Cargando…
CRLX101 (formerly IT-101)–A Novel Nanopharmaceutical of Camptothecin in Clinical Development
CRLX101 (formerly IT-101) is a first-in-class nanopharmaceutical, currently in Phase 2a development, which has been developed by covalently conjugating camptothecin (CPT) to a linear, cyclodextrin-polyethylene glycol (CD-PEG) co-polymer that self-assembles into nanoparticles. As a nanometer-scale dr...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Bentham Science Publishers Ltd
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3182091/ https://www.ncbi.nlm.nih.gov/pubmed/22081768 http://dx.doi.org/10.2174/157340711795163866 |
_version_ | 1782212869490737152 |
---|---|
author | Young, Cissy Schluep, Thomas Hwang, Jungyeon Eliasof, Scott |
author_facet | Young, Cissy Schluep, Thomas Hwang, Jungyeon Eliasof, Scott |
author_sort | Young, Cissy |
collection | PubMed |
description | CRLX101 (formerly IT-101) is a first-in-class nanopharmaceutical, currently in Phase 2a development, which has been developed by covalently conjugating camptothecin (CPT) to a linear, cyclodextrin-polyethylene glycol (CD-PEG) co-polymer that self-assembles into nanoparticles. As a nanometer-scale drug carrier system, the cyclodextrin polymeric nanoparticle technology, referred to as “CDP”, has unique design features and capabilities. Specifically, CRLX101 preclinical and clinical data confirm that CDP can address not only solubility, formulation, toxicity, and pharmacokinetic challenges associated with administration of CPT, but more importantly, can impart unique biological properties that enhance CPT pharmacodynamics and efficacy. |
format | Online Article Text |
id | pubmed-3182091 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2011 |
publisher | Bentham Science Publishers Ltd |
record_format | MEDLINE/PubMed |
spelling | pubmed-31820912011-11-10 CRLX101 (formerly IT-101)–A Novel Nanopharmaceutical of Camptothecin in Clinical Development Young, Cissy Schluep, Thomas Hwang, Jungyeon Eliasof, Scott Curr Bioact Compd Article CRLX101 (formerly IT-101) is a first-in-class nanopharmaceutical, currently in Phase 2a development, which has been developed by covalently conjugating camptothecin (CPT) to a linear, cyclodextrin-polyethylene glycol (CD-PEG) co-polymer that self-assembles into nanoparticles. As a nanometer-scale drug carrier system, the cyclodextrin polymeric nanoparticle technology, referred to as “CDP”, has unique design features and capabilities. Specifically, CRLX101 preclinical and clinical data confirm that CDP can address not only solubility, formulation, toxicity, and pharmacokinetic challenges associated with administration of CPT, but more importantly, can impart unique biological properties that enhance CPT pharmacodynamics and efficacy. Bentham Science Publishers Ltd 2011-03 /pmc/articles/PMC3182091/ /pubmed/22081768 http://dx.doi.org/10.2174/157340711795163866 Text en © 2011 Bentham Science Publishers Ltd http://creativecommons.org/licenses/by/2.5/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.5/), which permits unrestrictive use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Article Young, Cissy Schluep, Thomas Hwang, Jungyeon Eliasof, Scott CRLX101 (formerly IT-101)–A Novel Nanopharmaceutical of Camptothecin in Clinical Development |
title | CRLX101 (formerly IT-101)–A Novel Nanopharmaceutical of Camptothecin in Clinical Development |
title_full | CRLX101 (formerly IT-101)–A Novel Nanopharmaceutical of Camptothecin in Clinical Development |
title_fullStr | CRLX101 (formerly IT-101)–A Novel Nanopharmaceutical of Camptothecin in Clinical Development |
title_full_unstemmed | CRLX101 (formerly IT-101)–A Novel Nanopharmaceutical of Camptothecin in Clinical Development |
title_short | CRLX101 (formerly IT-101)–A Novel Nanopharmaceutical of Camptothecin in Clinical Development |
title_sort | crlx101 (formerly it-101)–a novel nanopharmaceutical of camptothecin in clinical development |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3182091/ https://www.ncbi.nlm.nih.gov/pubmed/22081768 http://dx.doi.org/10.2174/157340711795163866 |
work_keys_str_mv | AT youngcissy crlx101formerlyit101anovelnanopharmaceuticalofcamptothecininclinicaldevelopment AT schluepthomas crlx101formerlyit101anovelnanopharmaceuticalofcamptothecininclinicaldevelopment AT hwangjungyeon crlx101formerlyit101anovelnanopharmaceuticalofcamptothecininclinicaldevelopment AT eliasofscott crlx101formerlyit101anovelnanopharmaceuticalofcamptothecininclinicaldevelopment |